PTO-1449 REPRODUCED

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION

March 15, 2006

Mohamed Attawia

3518.1012-005 FIRST NAMED INVENTOR

ATTORNEY DOCKET NO.

APPLICATION NO. 10/714,594

FILING DATE

November 14, 2003

(Use several sheets if necessary)

EXAMINER CONFIRMATION NO. Standley, Steven H. 3230

GROUP 1649

	U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT				
.52	АН	4,427,649	01-24-1984	Dingle, et al.				
22 22	Al	5,095,037	03-10-1992	Iwamitsu, et al.				
8	ĄJ	5,116,964	05-26-1992	Capon, et al.				
22	AK	5,225,538	07-06-1993	Capon, et al.				
SS	AA2	5,231,024	07-27-1993	Moeller, et al.				
22	AB2	5,270,300	12-14-1993	Hunziker				
22	AC2	5,368,841	11-29-1994	Trauner, et al.				
SS	AD2	5,447,851	09-05-1995	Beutler, et al.				
22	AE2	5,510,370	04-23-1996	Hock				
22	AF2	5,656,272	08-12-1997	Le, et al.				
22	AG2	5,728,396	03-17-1998	Peery, et al.				
22	AH2	5,833,984	11-10-1998	Eibl, et al.				
35	AI2	5,942,499	08-24-1999	Radomsky				
22	AJ2	5,965,583	09-12-1999	Beers, et al.				
22	AK2	6,277,969	08-21-2001	Le, et al.				
\mathcal{L}	AA3	6,284,471	09-04-2001	Le, et al.				
\mathcal{S}	AB3	6,294,170	09-25-2001	Boone, et al.				
52	AC3	6,419,944	07-16-2002	Tobinick				
2	AD3	6,541,477	04-01-2003	Goehring, et al.				
2	AE3	6,554,830	04-29-2003	Chappius				
<u> [2</u>	AF3	6,590,081	07-08-2003	Zhang				
25	AG3	6,623,472	09-23-2003	Reinecke, et al.				
55	АН3	6,713,246	03-30-2004	Reinecke, et al.				
27	AI3	US 2001/0006948 A1	07-05-2001	Kang, et al.				
(2	AJ3	US 2001/0016195 A1	07-05-2001	Tobinick				

		··	
EXAMINER	Al	DATE CONSIDERED	
@PFDesktop\::ODMA/M	HODMA/HBSR05;iManage;604362;1		

PTO-1449 REPRODUCED SUPPLEMENTAL	ATTORNEY DOCKET NO. 3518.1012-005		PLICATION NO. /714,594		
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION March 15, 2006			FILING DATE November		
(Use several sheets if necessary)	EXAMINER Standley, Steven H.	CONF	IRMATION NO.	GROUP 1649	

		U.S. P.	ATENT DOCUMENTS	
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
55	AK3	US 2001/0026801 A1	10-04-2001	Tobinick
82	AA4	US 2002/0010471 A1	01-24-2002	Wironen, et al.
22	AB4	US 2002/0026244 A1	02-28-2002	Trieu
a	AC4	US 2002/0032155 A1	03-14-2002	Ferree
2	AD4	US 2002/0107200 A1	08-08-2002	Chang, et al.
22	AE4	US 2002/0198599 A1	12-26-2002	Haldimann
S.	AF4	US 2003/0007972 A1	01-09-2003	Tobinick
22	AG4	US 2003/0039651 A1	02-27-2003	Olmarker
2	AH4	US 2003/0049256 A1	03-13-2003	Tobinick
\mathcal{I}	AI4	US 2003/0207827 A1	11-06-2003	Boyle, et al.
22	AJ4	US 2003/0134792 A1	07-17-2003	Pike, et al.
S	AK4	US 2002/0169162	11-14-2002	Smith, et al.
-				
	_			
	-			
<u> </u>				
	4		V	

EXAMINER	DATE CONSIDERED

1649

PTO-1449 REPRODUCED

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION

March 15, 2006

(Use several sheets if necessary)

3518.1012-005	APPLICATION NO. 10/714,594
FIRST NAMED INVENTOR Mohamed Attawia	FILING DATE November 14, 2003
EXAMINER	CONFIRMATION NO. GROUP

3230

		F	OREIGN PATENT D	OCUMENTS		
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRAN YES	SLATION NO
2	AN	EP 0 218868 A2	04-22-1987	New York Blood Center, Inc.		
55	AO	EP 0 288 088 B1	10-26-1988	Teijin Limited		
S	ΑP	EP 0 438234 A1	07-24-1991	Kita		
22	AQ	EP 0 950417 A2	02-15-1999	Pfizer Products, Inc.		
ĴŜ	AL2	EP 1 133995 A2	09-19-2001	Synergen, Inc.		
SS	AM2	EP 1 153607 A2	11-14-2001	Dunn		
J.	AN2	WO 01/85179 A2	11-15-2001	Clemson University		
2	AO2	WO 02/057240 A1	07-25-2002	Ortho McNeil Pharmaceutical, Inc.		
Z.	AP2	WO 02/100387 A1	12-19-2002	A+ SCIENCE INVEST AB		
SS	AQ2	WO 03/000190 A2	01-03-2003	DePuy		
12.	AL3	WO 91/02078 A1	02-21-1991	Peptide Technology LTD		
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	AM3	WO 92/07076 A1	04-30-1992	The Charring Cross Sunley Research Centre		
35	AN3	WO 92/16553 A1	10-01-1992	New York University and Centocor, Inc.		
SS	AO3	WO 93/16099 A2	08-19-1993	Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka MBH		
SS	AP3	WO 97/28828 A1	08-14-1997	Amgen Boulder, Inc.		
55	AQ3	Intentionally Omitted		·		
SS	AL4	WO 98/24477 A1	06-11-1998	Amgen, Inc.		
3	AM4	WO 99/45923 A1	09-16-1999	Merck & Co., Inc.		

Standley, Steven H.

EXAMINER	T	DATE CONSIDERED
<u> </u>		9/1106
@PFDesktop\::ODMA/MHODMA/HBSR05;iManage;604	436	24

PTO-1449 REPRODUCED SUPPLEMENTAL	ATTORNEY DOCKET NO. 3518.1012-005		LICATION NO. /714,594	
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION March 15, 2006	The state of the s		FILING DATE November 14, 2003	
(Use several sheets if necessary)	EXAMINER Standley, Steven H.			GROUP 1649

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
S	AT5	Abstracts of the N. American Spine Society 17 Annual Meeting, Montreal, Canada, October 29 through November 2, 2002, <i>The Spine Journal</i> , 2(5Suppl.). 49S-50S (2002).
\$	AUS	Allai, F., et al., "Increase in Bone Mineral Density of Patients with Spondyloarthropathy Treated With Anti-Tumor Necrosis Factor α," Ann. Rheum. Dis., 62:347-349 (2003).
\$	AV5	Andonopoulos, A.P., et al., "Intra-articular Anti-Tumor Necrosis Factor α Antibody in Recalcitrant Arthritis of Behçet's Disease," Clinical and Experimental Rheumatology 21(4 Suppl 30): S-57-S58 (July-August 2003).
55.	AW5	Aoki, Y., et al., "Local Application of Disc-Related Cytokines on Spinal Nerve Roots," Spine, 27(15): 1614-1617 (2002).
55	AX5	Ariga, K., et al., "Mechanical Stress-Induced Apoptosis of Endplate Chondrocytes in Organ-Cultured Mouse Intervertebral Discs," Spine, 28(14): 1528-1533 (2003).
Z	AY5	Ashkenazi, A., et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin," Proc. Natl. Acad. Sci. USA, 88, pp. 10535-10539.
ડા	AZ5	Baker, D., et al., "Control Established Experimental Allergic Encephalomyelitis by Inhibition of Tumor Necrosis Factor (TNF) Activity Within the Central Nervous System using Monoclonal Antibodies and TNF Receptor-Immunoglobulin Fusion Proteins," Eur. J. Immunol., 24:2040-2048 (1994)
22	AR6	Biskobing, D. M., "Novel Therapies for Osteoporosis," Expert Opinion Invest. Drugs, 12(4): 611-621 (2003).
SJ	AS6	Bokarewa, M., et al., "Local Infusion of Infliximab for the Treatment of Acute Joint Inflammation," Ann. Rheum. Dis., downloaded from ard.bmjjournals.com on 30 November 2005, www.annrheumdis.com 62:783-784 (2003).
لي	AT6	Boehm, et al., "New Inhibitors of p38 Kinase," Exp. Opin, Ther. Patents, 10(1):25-37 (2000).
SS	AU6	Braun, J. and Sieper J., "Overview of The Use of The Anti-TNF Agent Infliximab in Chronic Inflammatory Diseases," Expert Opin. Biol. Ther. 3(1):141-168 (2003).
5	AV6	Braun, J., et al., "Anti-Tumour Necrosis Factor α Therapy for Ankylosing Spondylitis: International Experience," Ann. Rheum. Dis., 61(Supp. III):iii51-iii60 (2002).

EXAMINER DATE CONSIDERED 9101	 	//				
	<i>ild</i>		DATE CONSIDERED	9/1	101	

PTO-1449 REPRODUCED SUPPLEMENTAL	ATTORNEY DOCKET NO. 3518.1012-005	APPLICATION NO. 10/714,594		
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION March 15, 2006 (Use several sheets if necessary)			FILING DATE November 14, 2003	
	EXAMINER Standley, Steven H.	CONFIRMATION NO. 3230		GROUP 1649

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
S	AW6	Bringman, T.S. et al., "Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Application for Affinity Purification, Immunoassays, and as Structural Probes," Hybridoma, 6(5):489-507 (1987).
22	AX6	Brown, K., et al., "Gelatin/Chondroitin 6-Sulfate Microspheres for the Delivery of Therapeutic Proteins to the Joint," Arthritis. & Rheum., 41(12):2185-2195 (1998).
22	AY6	Burke, J.G., et al., "Intervertebral Discs Which Cause Low Back Pain Secrete High Levels of Proinflammatory Mediators," J. Bone Joint Surg. [Br] 84-B, 196-201 (2001).
22	AZ6	Butler, D. et al., "TNF Receptor Fusion Proteins are Effective Inhibitors of TNF-Mediated Cytotoxicity on Human KYM-1D4 Rhabdomyosarcoma Cells," Cytokine, 6(6):616-623 (1994).
D	AR7	Capon, D. et al. "Designing CD4 Immunoadhesins for AIDS Therapy," Nature, 337:525-531 (1989).
IJ	AS7	Cardone, D. A., et al., "Diagnostic and Therapeutic Injection of the Hip and Knee," Am. Fam. Physician, 67(10): 2147-2152 (2003).
SI	АТ7	Chae, H.J. et al., "The p38 Mitogen-Activated Protein Kinase Pathway Regulates Interleukin-6 Synthesis in Response to Tumor Necrosis Factor in Osteoblasts," Bone, 28(1): 45-53 (2001).
SS	AU7	Cirillo et al., "The Non-Diaryl Heterocycle Classes of p38 MAP Kinase Inhibitors," Current Topics in Medicinal Chemistry, 2: 1021-1035 (2002).
Z	AV7	Conti, F., et al., "Successful Treatment With Intraarticular Infliximab for Resistant Knee Monarthritis in a Patient With Spondylarthropathy," Arthritis & Rheumatism, 52(4): 1224-1226 (2005).
SS	AW7	Corcoran, A.E. et al., "Characterization of Ligand Binding by the Human p55 Tumour-Necrosis-Factor Receptor," Eur. J. Biochem., 223:831-840 (1994).
\mathcal{Z}	AX7	Crandall, C., "Combination Treatment of Osteoporosis: A Clinical Review," J. of Women's Health & Gender-Based Medicine, 11(3):211-224 (2002).
Ŋ	AY7	Dayer, J.M., "The Pivotal Role of Interleukin-1 in the Clinical Manifestations of Rheumatoid Arthritis," Rheumatology, Oxford University Press, London, GB, 42(Suppl 2):ii03-ii10 (2003).
2	AZ7	DeSantis, A. and Buchman, A., "Current and Emerging Therapies in Osteoporosis," Expert Opin. Pharmacother., 3(7):835-843 (2002).

EXAMINER	7	l	9	DATE CONSIDERED		l	106	
	_	هر:			≌	÷		

PTO-1449 REPRODUCED SUPPLEMENTAL	ATTORNEY DOCKET NO. 3518.1012-005	LICATION NO. 714,594			
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION March 15, 2006	FIRST NAMED INVENTOR Mohamed Attawia		FILING DATE November 14, 2003		
(Use several sheets if necessary)	EXAMINER Standley, Steven H.	CONF	IRMATION NO.	GROUP 1649	

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
\$	AR8	Diwan, A. D., et al., "Current Concepts in Intervertebral Disk Restoration," Tissue Engineering in Orthopedic Surgery, 31(3):453-464 (2000).
શ	AS8	Engelmann, H. et al., "Two Tumor Necrosis Factor-Binding Proteins Purified From Human Urine," J. Biol. Chem., 265(3):1531-1536 (1990).
st	AT8	Ezra, A., and Golomb, G., "Administration Routes and Delivery Systems of Bisphosphonates for the Treatment of Bone Resorption," Adv. Drug Del. Rev., 42:175-195 (2000).
S	AU8	Fendly et al., "Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor," Hybridoma, 6:359-370 (1987).
23	AV8	Gabay, C., "IL-1 Trap," Curr. Opin. Invest. Drugs, Curr. Drugs, London, GB, 4(5):593-597 (2003).
IJ	AW8	Goodman, S. et al., "Effects of Local Infusion of TGFβ on Bone Ingrowth in Rabbit Chambers," J. Biomed. Mat. Res. (Appl Biomater), 53:475-479 (2000).
SS	AX8	Gordon, J. L., et al., "Metalloproteinase Inhibitors as Therapeutics," Clin. Exp. Rheumatol., 11(Suppl. 8): S91-S94 (1993).
2	AY8	Goupille, P., et al., "Matrix Metalloproteinases The Clue to Intervertebral Disc Degeneration?," Spine, 23(14): 1612-1626 (1998).
5	AZ8	Hirai, M. et al., "Production and Characterization of Monoclonal Antibodies to Human Tumor Necrosis Factor," J. Immunol. Meth., 96:57-62 (1987).
J	AR9	Hunter, C. J., et al., "Functional Behaviour of Notochordal Cell Clusters in the Canine Nucleus Pulposus: Cell Communication and Survival," 70, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
22	AS9	Hydrogels, Encyclopedia of Polymer Science and Technology, (Wiley and Sons, 2003).
Zz	АТ9	Johnson, W.H., et al., "Collagenase Inhibitors: Their Design and Potential Therapeutic Use," J. Enzyme Inhib., 2:1-22 (1987).
S	AU9	Karppinen, J., et al., "Tumor Necrosis Factor- α Monoclonal Antibody, Infliximab, Used to Manage Severe Sciatica," Spine, 28(8):750-754 (2003).

	Ц	_			
EXAMINER	<u>C</u>		DATE CONSIDERED	1106	
@PFDeskton\"DDMAAAHC	1014	A /L	DCD05:34604262:1		_

PTO-1449 REPRODUCED SUPPLEMENTAL	ATTORNEY DOCKET NO. 3518.1012-005 APPLICATION NO. 10/714,594			
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION March 15, 2006	FIRST NAMED INVENTOR Mohamed Attawia		FILING DATE November 14, 2003	
(Use several sheets if necessary)	EXAMINER Standley, Steven H.	CONF 3230	IRMATION NO.	GROUP 1649

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
\$	AV9	Kawakami, M., et al., "Possible Mechanism of Painful Radiculopathy in Lumbar Disc Herniation," Clin. Orthop. 351:241-251(1998).
SS	AW9	Kimble, R.B. et al., "Estrogen Deficiency Increases the Ability of Stromal Cells to Support Murine Osteoclastogenesis Via an InterLeukin-1 and Tumor Necrosis Factor-Mediated Stimulation of Macrophage Colony-Stimulating Factor Production," J. Biol. Chem. 271(46):28890-28897 (1996).
Z	AX9	Kimble, R.B. et al., "The Functional Block of TNF but Not of IL-6 Prevents Bone Loss in Ovariectomized Mice," J. Bone Min. Res., 12(6):935-941 (1997).
Si	AY9	Koch, H. et al., "Spontaneous Secretion of Interleukin 1 Receptor Antagonist (IL-1Ra) by Cells Isolated From Herniated Lumbar Discal Tissue After Discectomy," Cytokine, 10(9): 703-705 (1998).
\$	AZ9	Kolls, J. et al. "Prolonged and Effective Blockade of Tumor Necrosis Factor Activity Through Adenovirus-Mediated Gene Transfer," Proc. Natl. Acad. Sci. USA, 91:215-219 (1994).
\$\$	AR10	LaVan, D. A., et al., "Small-Scale Systems for in vivo Drug Delivery," Nature, Biotechnology, 21(10):1184-1191 (2003).
Q	AS10	Lee, et al., "Inhibition of p38 MAP Kinase as a Therapeutic Strategy," Immunopharmacology, 47: 185-201 (2000).
2)	AT10	Lehman, T. J. A., et al., "Thalidomide Therapy for Recalcitrant Systemic Onset Juvenile Rheumatoid Arthritis," J. Pediatrics, 140(1):125-127 (2002).
S	AU10	Lesslauer, W., et al., "Recombinant Soluble Tumor Necrosis Factor Receptor Proteins Protect Mice from Lipopolysaccharide-Induced Lethality," Eur. J. Immunol., 21:2883-2886 (1991).
S	AV10	Liang, CM., et al., "Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin," Biochem. Biophys. Res. Comm. 137(2):847-854 (1986).
\$	AW10	Loetscher, H. et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor," Cell, 61:351-359 (1990).
Sj	AX10	Maeda, S. and Kokubun, S., "Changes With Age in Proteoglycan Synthesis in Cells Cultured In Vitro From the Inner and Outer Rabbit Annulus Fibrosus," Spine, 25(2):166-169 (2000).

	//			
EXAMINER	P	DATE CONSIDERED	9	101
@PFDesktop\::ODMA/MHODMA/HBSR05	;iManage;604362;1			

PTO-1449 REPRODUCED ATTORNEY DOCKET NO. APPLICATION NO. 10/714,594 3518.1012-005 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT FIRST NAMED INVENTOR FILING DATE IN AN APPLICATION Mohamed Attawia November 14, 2003 March 15, 2006 EXAMINER CONFIRMATION NO. GROUP Standley, Steven H. 3230 1649 (Use several sheets if necessary)

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
I	AY10	Meager, A. et al., "Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF)," Hybridoma, 6(3):305-311 (1987).
57	AZ10	Möller, A. et al., "Monoclonal Antibodies to Human Tumor Necrosis Factor α: In Vitro and In Vivo Application," Cytokine 2(3):162-169 (1990).
Ñ	AR11	Molloy, T., et al., "The Roles of Growth Factors in Tendon and Ligament Healing," Sports Med., 33(5): pp.381-394 (2003).
\$.	ASII	Müller, R. "Determination of Affinity and Specificity of Anti-Hapten Antibodies by Competitive Radioimmunoassay," <i>Meth. Enzymol.</i> , 92:589-601 (1983).
S	AT11	Nakamura, K. et al., "Local Application of Basic Fibroblast Growth Factor into the Bone Increases Bone Mass at the Applied Site in Rabbits," Arch. Orthop. Trauma Surg., 115(6):344-346 (1996).
5)	AUI1	Nakamura, K. et al., "Stimulation of Endosteal Bone Formation by Local Intraosseous Application of Basic Fibroblast Growth Factor in Rats," Rev. Rhum. [Engl. Ed.], 64(2):101-105 (1997).
\$	AVII	Nikas, S. N., et al., "Treatment of Resistant Rheumatoid Arthritis by Intra-Articular Infliximab Injections: A Pilot Study," Ann. Rheum. Dis., downloaded from ard.bmjjournals.com on 2 November 2005, www.annrheumdis.com 63: 102-103 (2004).
\$	AWII	Olmarker, K. and Rydevik, B., "Selective Inhibition of Tumor Necrosis Factor-\alpha Prevents Nucleus Pulposus-Induced Thrombus Formation, Intraneural Edema, and Reduction of Nerve Conduction Velocity," Spine, 26(8): 863-869 (2001).
\$	AX11	Pacifici, R., "Editorial: Cytokines, Estrogen, and Postmenopausal Osteoporosis-The Second Decade," Endocrinology, 139(6):2659-2661 (1998).
57	AYII	Pargellis, C. et al., "Inhibition of p38 MAP Kinase by Utilizing a Novel Allosteric Binding Site," Nature Structural Biology, 9(4): 268-272 (2002).
Sj	AZII	Pederson, A.W. et al., "Thermal Assembly of a Biomimetic Mineral/Collagen Composite," <i>Biomaterials</i> , 24:4881-4890 (2003).

		<u> </u>			
EXAMINER	lel.	DATE CONSIDERED	9/1	704	
@PFDeskton\"ODMA/MHODMA/HBSP05-iMen	nnge:604362-1				

@PFDesktop\::ODMA/MHODMA/HBSR05;iManage;604362;I

PTO-1449 REPRODUCED SUPPLEMENTAL	ATTORNEY DOCKET NO. 3518.1012-005	PLICATION NO. 1/714,594		
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION March 15, 2006	FIRST NAMED INVENTOR Mohamed Attawia	FILING DATE November 14, 2003		
(Use several sheets if necessary)	EXAMINER Standley, Steven H.			GROUP 1649

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
\$	AR12	Peppel, K. et al. "A Tumor Necrosis Factor (TNF) Receptor-IgG Heavy Chain Chimeric Protein as a Bivalent Antagonist of TNF Activity," J. Exp. Med., 174:1483-1489 (1991).						
5 5	AS12	Rodan, G.A. et al., "Therapeutic Approaches to Bone Diseases," Science, 289:1508-1514 (2000).						
S	AT12	Schall, T. et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor," Cell, 61:361-370 (1990).						
\$	AU12	Schatteman, L., et al., "Treatment of Refractory Inflammatory Monoarthritis in Ankylosing Spondylitis by Intraarticular Injection of Infliximab," J. Of Rheum., 33:1, pp. 82-85 (2006).						
55	AV12	Stern, S., et al., "Human Intervertebral Disc Cell Culture for Disc Disorders," Clin. Orthop., 419:238-244 (2004).						
SS	AW12	Takegami, K., et al., "Osteogenic Protein-1 Enhances Matrix Replenishment by Intervertebral Disc Cells Previously Exposed to Interleukin-1," Spine, 27(12):1318-1325 (2002).						
Z	AX12	Tobinick, E.L.and Davoodifar, S., "Perispinal TNF-alpha Inhibition for Discogenic Pain," Swiss Med. Weekly, 133:170-177 (2003).						
$\langle \mathcal{X} \rangle$	AY12	Tobinick, E.L., "Targeted Etanercept for Discogenic Neck Pain: Uncontrolled, Open-Label Results in Two Adults," Clin. Ther., 25(4):1211-1218 (2003).						
S	AZ12	Wittenberg, R.H., et al., "In Vitro Release of Prostaglandins and Leukotrienes From Synovial Tissue, Cartilage, and Bone in Degenerative Joint Diseases," Arthritis Rheum., 36(10):1444-1450 (1993).						
2	AR13	Yabuki, S., et al., "Prevention of Compartment Syndrome in Dorsal Root Ganglia Caused by Exposure to Nucleus Pulposus," Spine, 26(8):870-875 (2001).						
SS	AS13	Zhang, C., et al., "Mitogen-activated Protein (MAP) Kinase Regulates Production of Tumor Necrosis Factor-α and Release of Arachidonic Acid in Mast Cells," J. Biol. Chem., 272(20): 13397-13402 (1997).						
SS	AT13	http://arthritis.com/od/kneetreatments/g/viscosupplement_p.htm, 12-09-2005.						
(2)	AU13	Kozbor, D. and Roder, J.C., "The Production of Monoclonal Antibodies from Human Lymphocytes," Immunology Today, 4(3):72-79 (1983).						

	()			
EXAMINER	KI	DATE CONSIDERED	9/1/06	

@PFDesktop\::ODMA/MHODMA/HBSR05;iManage;604362;1

SUPPLEMENTAL SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION March 15, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. APPLICATION NO. 10/714,594					
	FIRST NAMED INVENTOR Mohamed Attawia Filing DATE November 14, 200					
	EXAMINER Standley, Steven H.	CONF. 3230	ONFIRMATION NO. GROUP 1649			

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
\$	AVI3	Lane, N.E., et al., "Basic Fibroblast Growth Factor Forms New Trabeculae That Physically Connect with Pre-Existing Trabeculae, and this New Bone is Maintained With an Anti-Resorptive Agent and Enhanced With an Anabolic Agent in an Osteopenic Rat Model," Osteoporos Int, 14: 374-382 (2003).						
23	AW13	Tobinick, E.L., "Targeted Etanercept for Treatment-Refractory Pain Due to Bone Metastasis: Two Case Reports," Clinical Therapeutics, 25(8):2279-2288 (2003).						
22	AX13	Vahle, J.L., et al., "Skeletal Changes in Rats Given Daily Subcutaneous Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and Relevance to Human Safety," Toxicologic Pathology, 30(3):312-321 (2002).						
31	AY13	Yaffe, A., et al., "Combined Local Application of Tetracycline and Bisphosphonate Reduces Alveolar Bone Resorption in Rats," <i>J Periodontol</i> , 74(7):1038-1042 (2003).						

				Sheet I o
PTO-1449 REPRODUCED SUPPLEMENTAL		SUPPLEMENTAL	ATTORNEY DOCKET NO. 3518.1012-005	APPLICATION NO. 10/714,594
i i		MATION DISCLOSURE STATEMENT IN AN APPLICATION	FIRST NAMED INVENTOR Mohamed Attawia	FILING DATE November 14, 2003
	OIPE	November 29, 2005 (Up) several sheets if necessary)	EXAMINER Steven Standley	CONFIRMATION NO. GROUP 3230 1649
 	EC 0 1 7	1005		
THE THE	_======================================	E/ U.S.	PATENT DOCUMENTS	
	REF. NO.		ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
53	AE	US 6,049,026	April 11, 2000	Muschler
72	AF	US 2005/0038001 A1	February 17, 2005	Attawia et al.
St	AG	US 2004/0229786 A1	November 18, 2004	Attawia et al.
	L			
<u> </u>				
		· · · · · · · · · · · · · · · · · ·		
		*		
L				

		1				_1
EXAMINER		/	DATE CONSIDERED		1	
				۲_	$\lfloor b \rfloor$	86
	Ī					

1649

PTO-1449 REPRODUCED

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION

November 29, 2005

(Use several sheets if necessary)

ATTORNEY DOCKET NO. 3518.1012-005	APPLICATION NO. 10/714,594	
FIRST NAMED INVENTOR Mohamed Attawia	FILING DATE November	14, 2003
FYAMINER	CONFIRMATION NO	GROUP

3230

	FOREIGN PATENT DOCUMENTS .								
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSI YES	LATION NO			
بخ	AL	WO 2004/022078 A1	March 18, 2004	The Royal Veterinary College, et al.					
36	AM	EP 1 464 307 A1	October 6, 2004	DePuy Spine, Inc.					
			-						
				·					
	<u>-</u>		·	,					
	-								

Steven Standley

	EXAMINER	Ll	DATE CONSIDERED		3 6
ì	@PFDeskton\:-ODMA/MHODMA/HBSR05-iManage: 577203-1/			-	

		PPLICATION NO. 0/714,594 FILING DATE November 14, 2003		
SAN AN APPLICATION Moh	NAMED INVENTOR named Attawia			
December 6, 2004 EXAM Not	MINER CON yet assigned 323	NFIRMATION NO.	GROUP 1614	

	U.S. PATENT DOCUMENTS						
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT			
<i>إ</i> ك	AD	US 2004/0193274 A1	09/30/2004	Trieu			
٠ م							
(
		;		1			
	:- <u>-</u> -						
				·			

ł	EXAMINER	_ / /	΄ Λ	DATE CONSIDERED			
1			<i>[</i>]	G	1	١	3 /
- 1		X	IJ	1 9	1 1	ı	0()
ı			*	<u> </u>	<u> </u>	\vdash	
- 1	PREPARENCE ON A MALODMA MECHASINA CONTRACTOR OF THE STATE				τ	•	

@PFDesktop\:ODMA/MHODMA/HBSR05;iManage;516236;1

PITO-1449 REPRODUCED	ATTORNEY DOCKET NO. APPLICATION NO. 3518.1012-005					
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANTS Mohamed Attawia et al.					
November 14, 2003 (Use several sheets if necessary)	FILING DATE November 14, 2003	CONFIRMATION NO. GROUP				

U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL	REF. NO.	TO COCUMENT NUMBER I .		NAME			
S	AA	6,340,369 B1	01/22/02	Ferree			
\mathcal{Z}	AB	6,352,557 B1	03/05/02	Ferree .			
22	AC	2003/0069639 A1	04/10/03	Sander et al.			

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
\$	AR	Alini, M., et al., "A Biological Approach to Treating Disc Degeneration: Not for Today, but Maybe for Tomorrow," Eur. Spine J., 11 (Suppl. 2): S215-S220 (2002).					
D	AS	Connolly, J., et al., "Development of an Osteogenic Bone-Marrow Preparation," The Journal of Bone and Joint Surgery, Inc., 71-A (5): 684-691 (1989).					
SS	AT	Ganey, T. M. and Meisel, H. J., "A Potential Role for Cell-Based Therapeutics in the Treatment of Intervertebral Disc Herniation," Eur. Spine J., 11 (Suppl. 2): S206-S214 (2002).					
S	AU	Sakai, D., et al., "Transplantation of Mesenchymal Stem Cells Embedded in Atelocollagen® Gel to the Intervertebral Disc: A Potential Therapeutic Model for Disc Degeneration," Biomaterials, 24: 3531-3541 (2003).					
Ŋ	AV	Ohtori, S., et al., "TNF-α and TNF-α Receptor 1 Upregulation in GLIA and Neurons After Nerve Injury. Studies in Murine DRG and Spinal Cord," 13, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
\$5	۸۷	Korhonen, T., et al., "Efficacy of Infliximab for Disc Herniation-Induced Sciatica One-Year Follow-Up," 14, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
5)	AX	Sakai, D., et al., "Autologous Transplantation of Mesenchymal Stem Cells for Disc Repair," 24, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
5)	AY	Le Visage, C., et al., "Interaction of Human Mescenchymal Stem Cells with Disc Cells: Changes in Biosynthesis of Extracellular Matrix," 25, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					

	7						
EXAMINER	T	Ω	DATE CONSIDERED	9		1	106
	=	\			_		

₹TO-1449 REPRODUCED	ATTORNEY DOCKET NO. APPLICATION NO. 3518.1012-005				
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANTS Mohamed Attawia et al.				
November 14, 2003 (Use several sheets if necessary)	FILING DATE November 14, 2003	CONFIRMATION NO.	GROUP		

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
\$	AZ	Risbud, M. V., et al., "Mesenchymal Stem Cells Respond to Their Microenvironment In Vitro to Assume Nucleus Pulposus-Like Phenotype," 26, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
2	AR2	Richardson, S., et al., "Human Bone Marrow Mesenchymal Stromal Cells as a Source of Chondrocytes for Treatment of Intervertebral Disc Degeneration," 27, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
S	AS2	Ahn, N. U., et al., "Effect of Nutrient Concentration and OP-1 on the Metabolism of Intervertebral Disc: In Vitro Organ Culture Study," 28, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
57	AT2	Kwon, U-H., et al., "Dexamethsone Stimulates Cellular Proliferation While Downregulates Matrix Synthesis in Intervertebral Disc Cells," 29, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
S	AU2	Li, J., et al., "The Effects of Bone Morphogenetic Protein 2 (BMP-2) and Cartilage-Derived Morphogentic Protein 2 (CDMP-2) on Aggrecan Gene Expression in Chondrocytes," 30, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
SS	AV2	Yoon, S. T., et al., "LMP-1 Upregulates Proteoglycan Synthesis in Intervertebral Disc Cells Through a BMP Mediated Process," 31, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
55	AW2	Cornefjord, M., et al., "Cerebrospinal Fluid Biomarkers in Experimental Spinal Nerve Root Injury," 38, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
\$	AX2	Takada, T., et al., "IL-6 Production was Upregulated by Interaction Between Disc Tissue and Macrophages," 41, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
\$	AY2	Inui, Y., et al., "Fas-Ligand Expression on Nucleus Pulposus Cells Begins in Developing Embryo," 42, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
55	AZ2	Sobajima, S., et al., "Stem Cell Therapy for Degenerative Disc Disease: An In-Vitro Feasibility Study," 43, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					

EXAMINER DATE CONSIDERED		0				
	EXAMINER	le.	DATE CONSIDERED	911	06	

*ETO-1449 REPRODUCED	ATTORNEY DOCKET NO. APPLICATION NO. 3518.1012-005				
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANTS Mohamed Attawia et al.				
November 14, 2003 (Use several sheets if necessary)	FILING DATE November 14, 2003	CONFIRMATION NO.	GROUP		

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
55	AR3	Imai, Y., et al., "The Quantification of Cytokine-Induced Matrix Catabolism in Tissue Engeneered Intervertebral Discs," 67, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
S	AS3	Hunter, C. J., et al., "Functional Behavior of Notochordal Cell Clusters in the Canine Nucleus Pulposus: Cell Communication and Survival," 70, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
J)	AT3	Tsuji, T., et al., "Age-Related Changes in M-RNA Expression of Various Regulatory Factors in Rabbit Intervertebral Disc," 81, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
SI	AU3	Miyamoto, H., et al., "The Effect of Mechanical Stress on the Production of Inflammatory Agents by Disc Cells," 110, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
SI	AV3	Arai, I., et al., "Pretreatment with Loxoprofen Sodium, 6-OHDA or Anti TNF-Alpha Antibody Reduce Fos-Like Immunoreactivity in Rat Experimental Lumber Disc Herniation," 111, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
5	AW3	Edwards, S. L., et al., "Radiographic Assessment of Posterolateral Spine Fusion With and Without Platelet Rich Plasma," 117, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
22	AX3	Xie, X., et al., "Treatment of Spondylodiscitis Intravenous Versus Percutaneous Intradiscal Applications of Antibiotics: An Experimental Study in Rabbits," 120, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
S	AY3	Frain, J., et al., "Use of cDNA Microarrays to Investigate Cytokine Expression in Intervertebral Disc Degeneration," 126, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
JS	AZ3	Hashizume, H., et al., "Role of IL-8, MCP-1 and PH in Neuropathic Pain Enhanced by Degenerative Nucleus Pulposus," 127, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
2)	AR4	Lotz, J. C., et al., "Cytokines in Normal, Degenerated, and Nucleoplasty-Treated Porcine Discs," 157, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					

1	EXAMINER	7 7.	/	DATE CONSIDERED
	1 /	\mathcal{X}		
	L			[ρ] [ρ]
	ODMANMUODMANManage:434048-1			

ŁTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3518.1012-005			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANTS Mohamed Attawia et al.			
November 14, 2003 (Use several sheets if necessary)	FILING DATE November 14, 2003	CONFIRMATION NO.	GROUP	

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
27	AS4	Okuma, M., et al., "Rotary Cell Culture System Stimulates Annulus Fibrosus Cell Proliferation but Suppresses Proteoglycan Metabolism," 164, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
ญ	AT4	Burke, J. G., et al., "Human Nucleus Pulposus Secretes Transforming Growth Factor Beta-1 and Basic Fibroblast Growth Factor," 189, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
55	AU4	Kato, H., et al., "The Effect of IL-1 on the Rabbit Intervertebral Disc In Vivo," 199, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
22	AV4	Imai, Y., et al., "Effect of Recombinant Human Osteogenic Protein-1 on Extracellular Matrix Metabolism by Human Annulus Fibrosus and Nucleus Pulposus Cells," 205, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
52	AW4	Lee, C. S., et al., "A Single Period of Hyperphysiologic Stretch Induces IL-6, TGF-beta and Cell Proliferation in Anulus Fibrosus Cells," 215, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
25	AX4	Le Maitre, C. L., et al., "Response of Human Intervertebral Disc Cells to IL-1," 216, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
SS	AY4	Le Maitre, C. L., et al., "Expression of the IL-1 Family in Human Intervertebral Disc," 217, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
S	AZ4	Weiler, C., et al., "Expression of TNF-α in Autopsy and Biopsy Specimens of Intervertebral Discs of Various Age and Degeneration," 233, Abstracts of the 30 th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
SS	AR5	Ohtori, S., et al., "TNF-\alpha-Deficient Mice Have Fewer Macrophages in Injured Nerve and Reduced Glial Activation in DRG and Spinal Cord," 250, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					
5)	AS5	Igarashi, A., et al., "Inflammatory Cytokines Release From Facet Joint Tissue in Degenerative Lumbar Disorders," 262, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).					

	//	
EXAMINER	7/ 0	DATE CONSIDERED
		9 11106
CDVANAGORA	124049.1	